AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
AVROBIO’s analyst and investor event will expand on the presentations at the conference and highlight AVROBIO’s progress with the Phase 1 study and Phase 2 FAB-201 study1 for its lead clinical program in Fabry disease; the Company’s optimized gene therapy platform; and other gene therapy pipeline programs in Gaucher, Cystinosis and Pompe. Featured speakers at the analyst and investor event include
AVR‑RD‑01 is a gene therapy being investigated in patients with Fabry disease. Designed to be a one-time therapy, its mechanism of action is by inserting the GLA gene that encodes functional αgalactosidase A (AGA, the enzyme that is deficient in Fabry disease), with the goal of enabling continuous AGA production and distribution to tissues and organs. The data related to the AVR‑RD-01 clinical program in Fabry disease presented at WORLDSymposium includes:
Platform presentation: “FACTs Fabry gene therapy clinical trial: Phase 1 study update and two-year data for first patient”
Study: Investigator-sponsored Phase 1 study of AVR-RD-01 conducted by the FACTs team (Fabry disease Clinical research and Therapeutics) in Canada
Poster presentation: “Evaluating the Content Validity of the Diary of Irritable Bowel Syndrome Symptoms - Mixed (DIBSS-M) to Assess Gastrointestinal Symptoms Associated with Fabry”
Presenter: Dawn Phillips Ph.D., Senior Clinical Scientist,
For AVROBIO’s analyst and investor event, a live webcast of the presentation and accompanying slides will be available under “Events and Presentations” in the Investors section of the Company’s website at www.avrobio.com. An archived webcast recording of the event will be available on the website for approximately 30 days.
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements about presenting at the WORLDSymposium annual conference and the types of data expected to be disclosed at the WORLDSymposium including the adjacent analyst and investor presentation. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.
Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any of AVROBIO’s ongoing or planned clinical trials, the risk that
1 The official name of the ‘FAB-201 study’ is AVRO-RD-01-201, which is a Phase 2 trial of AVROBIO’s investigational gene therapy AVR-RD-01, in Fabry disease.
Christopher F. Brinzey Westwicke Partners339-970-2843 email@example.com Media Contact: Kathryn MorrisThe Yates Network 914-204-6412 firstname.lastname@example.org
Source: AVROBIO, Inc.